Payment guidance for researchers and professionals involving people in research

1:1

This guidance has been compiled for a wide audience, but in particular it will be of value to:

  • researchers who need to cost public involvement activities at any stage of the research process
  • anyone in a professional role involved in costing public involvement or advising researchers on budgeting for involvement
  • public contributors who want to know how their involvement in research is costed
  • research advisors/managers who provide guidance to the research community about involvement
  • commissioners of research who invite funding applications from the research community
  • reviewers and panel members who appraise research projects with costed involvement activities

We have developed a separate guidance document aimed at public contributors, which you might also want to view.

Acces this publication
jarmoluk-money-256305_1920

Year of publication

2026

Author

NIHR

You might also be interested in

2

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.
ERDERA Open Academy 2026

Open Academy x ERDERA Schools in Barcelona strengthen practical links between patient advocacy and rare disease research

The 2026 Open Academy x ERDERA Schools in Barcelona brought patient advocates and early-career researchers together for practical training on medicines development, translational research and meaningful participation in rare disease research.
Sveriges riksdag (house of parlament).

Sweden adopts first national strategy for rare health conditions

Sweden has adopted its first national strategy for rare health conditions, aiming to improve coordination, equity and access to care between 2026 and 2030.

ERDERA's

search form